Suppression of lipoprotein lipase expression in 3T3-L1 cells by inhibition of adipogenic differentiation through activation of the renin-angiotensin system

Metabolism: Clinical and Experimental

Volumn 57, Issue 8, 2008, Pages 1093-1100

  Saiki, Atsuhito ^a   Koide, Nobukiyo ^a   Watanabe, Fusako ^a   Murano, Takeyoshi ^a   Miyashita, Yoh ^a   Shirai, Kohji ^a  

^a TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; LIPOPROTEIN LIPASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; VALSARTAN;

ANIMAL CELL; ARTICLE; CELL SIZE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REPRESSION; INCUBATION TIME; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

3T3-L1 CELLS; ADIPOCYTES; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSINOGEN; ANIMALS; AZO COMPOUNDS; BLOTTING, WESTERN; CELL DIFFERENTIATION; LIPOPROTEIN LIPASE; MICE; MICROSCOPY, PHASE-CONTRAST; PPAR GAMMA; RENIN-ANGIOTENSIN SYSTEM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TETRAZOLES; THIAZOLIDINEDIONES; VALINE;

EID: 47149096597     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.03.014     Document Type: Article

References (33)

1. Nilsson-Ehle P.A., Garfinkel A.S., and Schotz M.C. Lipolytic enzymes and plasma lipoprotein metabolism. Annu Rev Biochem 49 (1980) 667-693
2. Louis C.S., and Henry J.P. Lipoprotein lipase, lipases (1984), Elsevier, Amsterdam 263-305
3. Braun J.E.A., and Severson D.L. Regulation of the synthesis, processing and translocation of lipoprotein lipase. Biochem 287 (1992) 337-347
4. Saxena U., Klein M.G., and Goldberg I.J. Transport of lipoprotein lipase across endothelial cells. Proc Natl Acad Sci U S A 88 (1991) 2254-2258
5. Shirai K., Itoh Y., Sasaki H., et al. The effect of insulin sensitizer, troglitazone, on lipoprotein lipase mass in preheparin serum. Diabetes Res Clin Pract 46 (1999) 35-41
6. Watanabe H., Miyashita Y., Murano T., et al. Preheparin serum lipoprotein lipase mass level: the effects of age, gender, and types of hyperlipidemias. Atherosclerosis 145 (1999) 45-50
7. Hanyu O., Miida T., Obayashi K., et al. Lipoprotein lipase (LPL) mass in preheparin serum reflects insulin sensitivity. Atherosclerosis 174 (2004) 385-390
8. Kobayashi J., Saito K., Fukamachi I., et al. Pre-heparin plasma lipoprotein lipase mass: correlation with intra-abdominal visceral fat accumulation. Horm Metab Res 33 (2001) 412-416
9. Saiki A., Oyama T., Endo K., et al. Preheparin serum lipoprotein lipase mass might be a biomarker of metabolic syndrome. Diabetes Res Clin Pract 76 (2007) 93-101
10. Saiki A., Ohira M., Endo K., et al. The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension. Diabetes Res Clin Pract 74 (2006) 242-248
11. Hirsch J., and Batchelor B. Adipose tissue cellularity in human obesity. Clin Endocrinol Metab 5 (1976) 299-311
12. van Harmelen V., Skurk T., Röhrig K., et al. Effect of BMI and age on adipose tissue cellularity and differentiation capacity in women. Int J Obes Relat Metab Disord 27 (2003) 889-895
13. Engfeldt P., and Arner P. Lipolysis in human adipocytes, effects of cell size, age and of regional differences. Horm Metab Res Suppl 19 (1988) 26-29
14. Despres J.P., Fong B.S., Julien P., et al. Regional variation in HDL metabolism in human fat cells: effect of cell size. Am J Physiol 252 (1987) E654-E659
15. Tontonoz P., Hu E., and Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79 (1994) 1147-1156
16. Braissant O., Foufelle F., Scotto C., et al. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137 (1996) 354-366
17. Hansson L., Lindholm L.H., Niskanen L., et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 353 (1999) 611-616
18. Yusuf S., Gerstein H., Hoogwerf B., et al. HOPE Study Investigators. Ramipril and the development of diabetes. JAMA 286 (2001) 1882-1885
19. Dahlof B., Devereux R.B., Kjeldsen S.E., et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359 (2002) 995-1003
20. Julius S., Kjeldsen S.E., Weber M., et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 363 (2004) 2022-2031
21. Bosch J., Yusuf S., Gerstein H.C., et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 355 (2006) 1551-1562
22. Engeli S., Negrel R., and Sharma A.M. Physiology and pathophysiology of the adipose tissue renin-angiotensin system,. Hypertension 35 (2000) 1207-1270
23. Janke J., Engeli S., Gorzelniak K., et al. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 51 (2002) 1699-1707
24. Hamilton B.S., Paglia D., Kwan A.Y., et al. Increased obese mRNA expression in omental fat cells from massively obese humans. Nat Med 1 (1995) 953-956
25. Lonnqvist F., Nordfors L., Jansson M., et al. Leptin secretion from adipose tissue in women. Relationship to plasma levels and gene expression. J Clin Invest 99 (1997) 2398-2404
26. Guo K.Y., Halo P., Leibel R.L., et al. Effects of obesity on the relationship of leptin mRNA expression and adipocyte size in anatomically distinct fat depots in mice. Am J Physiol Regul Integr Comp Physiol 287 (2004) R112-R119
27. Skurk T., Alberti-Huber C., Herder C., et al. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab 92 (2007) 1023-1033
28. Crandall D.L., Armellino D.C., Busler D.E., et al. Angiotensin II receptors in human preadipocytes: role in cell cycle regulation. Endocrinology 140 (1999) 154-158
29. Folli F., Saad M.J., Velloso L., et al. Crosstalk between insulin and angiotensin II signalling systems. Exp Clin Endocrinol Diabetes 107 (1999) 133-139
30. Wallinder L., Peterson J., Olivecrona T., et al. Hepatic and extrahepatic uptake of intravenously injected lipoprotein lipase. Biochim Biophys Acta 795 (1984) 513-524
31. Brink M., Wellen J., and Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest 97 (1996) 2509-2516
32. Cabassi A., Coghi P., Govoni P., et al. Sympathetic modulation by carvedilol and losartan reduces angiotensin II-mediated lipolysis in subcutaneous and visceral fat. J Clin Endocrinol Metab 90 (2005) 2888-2897
33. Townsend R.R. The effects of angiotensin-II on lipolysis in humans. Metabolism 50 (2001) 468-472